{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:41Z","timestamp":1792787261285,"version":"4.5.0"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Center for Drug Evaluation and Research at the US FDA","award":["75F40120C0044"],"award-info":[{"award-number":["75F40120C0044"]}],"id":[{"id":"https:\/\/ror.org\/00yf3tm42","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K01AG068365"],"award-info":[{"award-number":["K01AG068365"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Until June 2025, individuals initiating clozapine in the USA were required to undergo routine haematological testing in accordance with the Clozapine Risk Evaluation and Mitigation Strategy (REMS) programme. Although the Clozapine REMS programme was eliminated in June 2025, clinical and prescribing recommendations on testing remained intact. Little is known, however, about adherence to testing requirements in practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to assess the prevalence and frequency of haematological testing in patients on clozapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort study using three US health insurance claims databases (1 January 2000\u201331 March 2022) assessed (1) proportion of individuals with at least one haematological test (white blood cell count with differential) prior to clozapine initiation and (2) frequency of testing (number of tests per 30 days of follow-up) during months 0\u20136, 7\u201312 and 13\u201324 of clozapine therapy. Tests were identified based on billing codes; patients hospitalised during the assessment period were assumed to have received testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>A total of 62\u2009003 clozapine initiations (mean (SD) age, 36 (15) years; 57% male) were identified, of which 71% were preceded by testing within 60 prior days. The mean (SD) testing rate while on therapy was 2.2 (1.8) tests per patient for each 30-day period during the first 6 months of treatment, 2.0 (1.8) tests per 30 days during months 7\u201312 and 1.5 (1.4) tests per 30 days during months 13\u201324.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study of individuals initiating clozapine in the USA, haematological testing was completed at a lower-than-expected rate prior to clozapine initiation and during the first 6 months of treatment but was in accordance with testing requirements thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Although clozapine drug labelling recommends routine haematological testing, especially during the first 6 months of treatment, such testing may not consistently occur. Reasons for less-than-recommended testing frequency should be further investigated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2026-302578","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:10:11Z","timestamp":1783685411000},"page":"e302578","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and frequency of haematological testing in patients initiating clozapine in the USA"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-5412","authenticated-orcid":false,"given":"Katsiaryna","family":"Bykov","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Mahesri","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren V","family":"Moran","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Psychotic Disorders, McLean Hospital, Belmont, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Program On Regulation, Therapeutics, And Law, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Lii","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita A","family":"Toyserkani","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H","family":"Zhou","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"LaCivita","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J","family":"Dal Pan","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Program On Regulation, Therapeutics, And Law, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-6206","authenticated-orcid":false,"given":"Ameet","family":"Sarpatwari","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Program On Regulation, Therapeutics, And Law, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2026091806105862000_29.1.e302578.1","first-page":"22","article-title":"A historical perspective of clozapine","volume":"60 Suppl 12","author":"Hippius","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"2026091806105862000_29.1.e302578.2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"2026091806105862000_29.1.e302578.3","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"2026091806105862000_29.1.e302578.4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"2026091806105862000_29.1.e302578.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2026091806105862000_29.1.e302578.6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300180"},{"key":"2026091806105862000_29.1.e302578.7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamapsychiatry.2023.0376","article-title":"International Variation in Clozapine Hematologic Monitoring-A Call for Action","volume":"80","author":"Oloyede","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"2026091806105862000_29.1.e302578.8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamapsychiatry.2019.1656","article-title":"Clozapine and Evidence-Based Psychopharmacology for Schizophrenia","volume":"76","author":"Stroup","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2026091806105862000_29.1.e302578.9","doi-asserted-by":"crossref","DOI":"10.1017\/S204579602200066X","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"31","author":"Oloyede","year":"2022","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2026091806105862000_29.1.e302578.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-023-00353-0","article-title":"What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians","volume":"9","author":"Oloyede","year":"2023","journal-title":"Schizophrenia (Heidelb)"},{"key":"2026091806105862000_29.1.e302578.11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.psychres.2019.03.029","article-title":"Psychiatrists\u2019 attitude towards the use of clozapine in the treatment of refractory schizophrenia: A nationwide survey","volume":"275","author":"Daod","year":"2019","journal-title":"Psychiatry Res"},{"key":"2026091806105862000_29.1.e302578.12","unstructured":"US Food and Drug Administration . November 19, 2024 joint meeting of the drug safety and risk management advisory committee and the psychopharmacologic drugs advisory committee- fda presentations. 2025. Available: https:\/\/www.fda.gov\/media\/183654\/download [Accessed 12 Apr 2026]."},{"key":"2026091806105862000_29.1.e302578.13","unstructured":"US Food and Drug Administration . Approved risk evaluation and mitigation strategies (REMS). Clozapine. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=RemsDetails.page&REMS=351 [Accessed 20 Jun 2024]."},{"key":"2026091806105862000_29.1.e302578.14","unstructured":"US Food and Drug Administration . Policy for certain rems requirements during the COVID19 public health emergency. 2020. Available: www.supremecourt.gov\/opinions\/URLs_Cited\/OT2020\/20A34\/20A34-5.pdf [Accessed 22 Apr 2026]."},{"key":"2026091806105862000_29.1.e302578.15","unstructured":"US Food and Drug Administration . Clozapine rems modification. 2025. Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/frequently-asked-questions-clozapine-rems-modification [Accessed 12 Apr 2026]."},{"key":"2026091806105862000_29.1.e302578.16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40264-021-01070-2","article-title":"A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs","volume":"44","author":"Sarpatwari","year":"2021","journal-title":"Drug Saf"},{"key":"2026091806105862000_29.1.e302578.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.10.012"},{"key":"2026091806105862000_29.1.e302578.18","unstructured":"US Food and Drug Administration . Clozaril labeling-package insert. 2025. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/019758s106lbl.pdf [Accessed 12 Apr 2026]."},{"key":"2026091806105862000_29.1.e302578.19","unstructured":"US Food and Drug Administration . What\u2019s changed in the clozapine rems for prescribers. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/rems\/Clozapine_2023_09_29_Factsheet_What\u2019s_Changed_with_the_Clozapine_REMS_Program_for_Prescribers.pdf [Accessed 3 Jun 2024]."},{"key":"2026091806105862000_29.1.e302578.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1977.tb00224.x"},{"key":"2026091806105862000_29.1.e302578.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"2026091806105862000_29.1.e302578.22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026091806105862000_29.1.e302578.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2025-302122","article-title":"Risk of neutropenia-related hospitalisation among clozapine initiators","volume":"29","author":"Sarpatwari","year":"2026","journal-title":"BMJ Ment Health"},{"key":"2026091806105862000_29.1.e302578.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2026-302578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:11:40Z","timestamp":1789737100000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2026-302578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,10]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjment-2026-302578"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2026-302578","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}